This list is based on the watchlists of people on Stock Events who follow IMV.TO. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Show more...
FAQ
What is IMV stock price today?▼
The current price of IMV.TO is C$1.12 CAD — it has decreased by -1.75% in the past 24 hours. Watch IMV stock price performance more closely on the chart.
What is IMV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IMV stocks are traded under the ticker IMV.TO.
What is IMV revenue for the last year?▼
IMV revenue for the last year amounts to 0 CAD.
What is IMV net income for the last year?▼
IMV.TO net income for the last year is -49.9M CAD.
How many employees does IMV have?▼
As of April 01, 2026, the company has 97 employees.
In which sector is IMV located?▼
IMV operates in the Healthcare sector.
When did IMV complete a stock split?▼
IMV has not had any recent stock splits.
Where is IMV headquartered?▼
IMV is headquartered in Dartmouth, CA.